会上，江门市市场监管局介绍了通过"益企维"平台在跨区域协作、执法能力提升等方面取得的成效，特 别是"新会陈皮"地理标志产品通过"益企维"知识产权保护联盟机制获得的保护成效。依托这一全国性协 作机制，不仅拓展了知识产权保护的覆盖面，还提升了案件办理效率和执法水平。 为深化知识产权跨区域跨部门协同保护，系统总结"益企维"创新实践经验，探索保护协作新模式新路 径，进一步优化营商环境，在第十四届中国知识产权年会期间，由福建省漳州市市场监督管理局主办 的"益企维"知识产权协同保护机制创新推进会在北京成功召开。江门市市场监督管理局作为协作单位代 表在会上作交流发言。 下一步，江门市市场监管局将继续依托"益企维"知识产权联盟协作机制，深化与各成员单位的沟通协 作，共同推动知识产权协同保护工作创新发展，为优化营商环境提供有力支撑。 据悉，"益企维"机制目前已覆盖全国19个省区的56个地市63个成员单位，成为知识产权保护领域重要的 协作平台。各成员单位通过该机制积极开展地理标志等知识产权保护协作，累计办理案件225件，为企 业节约维权成本2300多万元。 ...

Core Viewpoint - Shenzhen SanTai E-commerce Co., Ltd. is benefiting from the depreciation of the RMB and is actively developing AI-driven tools for risk detection in cross-border e-commerce [2][3]. Company Overview - Shenzhen SanTai E-commerce Co., Ltd. was established on January 7, 2008, and is located in Nanshan District, Shenzhen, Guangdong Province. The company primarily engages in cross-border e-commerce retail and logistics [7]. - The company's revenue composition includes 76.14% from cross-border e-commerce product sales, 23.80% from logistics sales, and minimal contributions from technology services and other businesses [7]. Business Developments - The company launched its AI-based intellectual property risk detection tool "RuiGuan·ERiC" for trial use on September 28, 2023, aimed at providing flexible and cost-effective risk monitoring solutions [2][3]. - The company is also developing an AIGC project that utilizes Stable Diffusion for generating high-quality images, enhancing operational efficiency and reducing production costs [2]. Financial Performance - For the first half of 2025, the company reported a revenue of 827 million yuan, representing a year-on-year growth of 3.27%, while the net profit attributable to shareholders decreased by 48.75% to 23.26 million yuan [8]. - As of September 19, 2023, the number of shareholders increased to 30,500, with an average of 7,192 circulating shares per person [8]. Market Position - The company operates in the cross-border e-commerce sector, which is part of the broader internet retail industry. It is positioned within several concept sectors, including intellectual property, express delivery, and small-cap stocks [8]. - The company's overseas revenue accounted for 99.98% of its total revenue, benefiting from the depreciation of the RMB [3].

近日，厦门金达威集团股份有限公司及子公司厦门金达威生物科技有限公司收到国家知识产权局颁发的 发明专利证书。发明名称为"一种辅酶Q10油剂及其制备方法和应用"，专利号ZL202310111297.8，申请 日为2023年，专利权期限二十年，授权公告日为2025年。该发明涉及辅酶Q10技术领域，其辅酶Q10油 剂中辅酶Q10高含量下能稳定以分子形态存在、生物利用度高。此专利取得虽不对公司生产经营产生重 大影响，但利于技术创新、完善知识产权保护体系及增强核心竞争力。 ...

Core Insights - The article emphasizes the importance of intellectual property (IP) protection as a core element of international competitiveness for businesses in the context of global digital trade [1][2] - The launch of the "Overseas Version of Hangzhi AI" by the Hangzhou Intellectual Property Protection Center represents a significant innovation in integrating AI technology with IP protection services [1][4] Group 1: Digital Trade and IP Protection - The fourth Global Digital Trade Expo will take place from September 25 to 29, 2025, showcasing the integration of AI and IP protection [1] - The Hangzhou Intellectual Property Protection Center aims to create a comprehensive smart IP service system that operates "all-time, all-domain, and all-chain" [1][2] Group 2: AI Integration and Services - The "Overseas Version of Hangzhi AI" is designed to enhance the existing "Zhinanzhen" service by providing tailored solutions for companies facing overseas IP challenges [2][3] - This AI tool addresses common pain points for businesses venturing abroad, such as unfamiliarity with overseas regulations and difficulties in resource selection [3] Group 3: Achievements and Innovations - Hangzhou has established itself as a national leader in digital economy IP protection, with over 80% of specialized enterprises in the digital economy sector registered [4][5] - The city has implemented a rapid patent pre-examination service, significantly reducing the authorization cycle for invention patents to under 80 days [4][5] Group 4: Future Outlook - The Hangzhou Intellectual Property Protection Center is committed to enhancing overseas IP risk warning mechanisms and dispute response strategies, with the AI tool being a key part of this initiative [5] - The center aims to leverage its digital economy advantages to create a more intelligent and efficient IP service system for businesses expanding globally [5]

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a Canadian patent related to its drug candidate Annamycin, which is being developed for the treatment of hard-to-treat cancers, particularly acute myeloid leukemia and soft tissue sarcoma lung metastases [1][2][3] Group 1: Patent and Intellectual Property - The Canadian patent application covers methods for producing a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until June 2040 [2] - The company is actively building its global intellectual property portfolio for Annamycin, which includes patents in the U.S., Europe, and other major jurisdictions [3] Group 2: Drug Development and Clinical Trials - Annamycin is positioned to be the first non-cardiotoxic anthracycline approved for use, with Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases [3][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [5] Group 3: Additional Pipeline and Research - In addition to Annamycin, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for potential treatment of pathogenic viruses and certain cancer indications [6]

Core Viewpoint - The company Suhao Hongye experienced a decline in stock price and trading volume, indicating potential market challenges and investor sentiment issues [1] Company Overview - Suhao Hongye Co., Ltd. is located in Nanjing, Jiangsu Province, and was established on June 30, 1994, with its stock listed on September 1, 1997 [6] - The company's main business includes trade (import and export, domestic trade) and cultural services (cultural engineering, art management, cultural venue operations, and cultural creative product development and sales) [6] - The revenue composition is as follows: 98.45% from product sales, 1.05% from engineering projects and consulting services, and 0.51% from other sources [6] Financial Performance - For the first half of 2025, Suhao Hongye achieved a revenue of 3.919 billion yuan, representing a year-on-year growth of 10.73% [6] - The net profit attributable to the parent company was 26.2955 million yuan, showing a year-on-year increase of 34.72% [6] - The company has distributed a total of 503 million yuan in dividends since its A-share listing, with 74.0302 million yuan distributed in the last three years [7] Investment and Shareholding - The company holds a 16.31% stake in Hongye Futures, which is the second-largest shareholder, and Hongye Futures is listed on the Hong Kong Stock Exchange [2] - Suhao Hongye's subsidiary, Jiangsu Aitao Cultural Industry Co., Ltd., holds a 28% stake in Jiangsu Cultural Property Exchange Co., Ltd. [2] - The company invested 12 million yuan for a 24% stake in Jiangsu Hongrui Technology Investment Co., Ltd., the first venture capital firm in Jiangsu Province focused on the biopharmaceutical sector [2] Market Activity - On September 25, the stock price of Suhao Hongye fell by 1.65%, with a trading volume of 44.5315 million yuan and a turnover rate of 1.76%, resulting in a total market capitalization of 2.507 billion yuan [1] - The main capital flow showed a net outflow of 4.8943 million yuan, indicating a lack of strong buying interest from major investors [3][4] Technical Analysis - The average trading cost of the stock is 10.88 yuan, with recent reductions in shareholding but at a slowing rate [5] - The current stock price is near a resistance level of 10.42 yuan, suggesting potential for a pullback unless this level is breached, which could lead to an upward trend [5]

Group 1 - The core viewpoint of the news is that China has improved its ranking in the Global Innovation Index to 10th place, marking its first entry into the top ten globally, reflecting significant achievements in innovation-driven development strategies [1] - The Global Innovation Index evaluates the innovation ecosystem performance of 139 economies based on innovation input and output, showing that China's ranking has risen by 25 places since 2013 [1] - Nanjing ranks 15th in the global innovation cluster ranking and 5th among domestic clusters, based on metrics such as international patent applications, scientific publications, and new venture capital transactions [1] Group 2 - Nanjing's PCT application volume is 8,241.81, accounting for 0.63% of the global total, ranking 20th among the top clusters; its scientific publication volume is 136,094, representing 1.66% of the global total, ranking 5th; and the new venture capital transaction volume is 1,266, accounting for 0.54%, ranking 35th [2] - Nanjing has been recognized as a national model city for intellectual property protection and has achieved significant results in intellectual property strategy implementation, with patent quality indicators ranking first in the province for four consecutive years [2] - As of June 2025, Nanjing has a high-value invention patent ownership of 77.99 per ten thousand people, and the effective invention patents in the digital economy industry account for 62.9% of the total effective invention patents in the region, maintaining the top position in the province [2] Group 3 - Nanjing aims to leverage high-quality development of intellectual property to support high-quality economic and social development, focusing on becoming a leading city in intellectual property creation, utilization, protection, management, and service [3] - The city is committed to enhancing its intellectual property capabilities to better serve innovation-driven development and contribute to the modernization of Nanjing [3]

Core Viewpoint - The company has received a utility model patent certificate from the National Intellectual Property Administration for a "fixed device for transporting new energy crucibles," which enhances its core competitiveness and protects its intellectual property [1] Group 1 - The patent acquisition is expected to promote the company's continuous innovation mechanism [1] - The new patent is aimed at improving the efficiency and safety of transporting new energy crucibles [1] - This development reflects the company's commitment to strengthening its technological capabilities [1]

Core Viewpoint - Zhejiang Tailin Biotechnology Co., Ltd. has recently obtained five patent certificates, which will enhance its intellectual property protection and maintain its technological leadership in the industry [4]. Patent Acquisition Summary - The company’s wholly-owned subsidiary, Zhejiang Tailin Life Science Co., Ltd., has acquired five patents, including one invention patent. The details are as follows: - Patent for gas sterilization resistance detection device and method (Invention) [4] - Appearance patents for two types of plankton pretreatment equipment, a stationary sampler, and a compressed air microbiological testing instrument [4]. - The patents are expected to strengthen the company's innovation mechanism and core competitiveness, although they will not have a significant immediate impact on production and operations [4].

近年来，创新药企业对创新成果保护愈加重视、仿制药企业对推动产品上市需求迫切。聚焦医药集中采 购领域知识产权痛点问题，《通知》提出三大举措：建立源头承诺制度，强化企业主体责任；构建快速 响应体系，提升纠纷处理效率；强化协同监管闭环，形成长效保护机制。 本报讯(记者蔡姝雯)记者从省知识产权局获悉，截至2025年7月，江苏生物医药集群发明专利拥有量4.62 万件，位居全国第一。为进一步规范创新药和仿制药平衡发展、有序竞争，推动我省生物医药产业更高 质量发展，近日省知识产权局联合省医疗保障局印发《关于加强医药集中采购领域知识产权保护工作的 通知》，通过建立完善"承诺—核查—处置"全链条知识产权保护机制，精准预防和高效化解医药集中采 购领域专利纠纷。 《通知》明确，江苏将成立省知识产权技术调查中心，为医药集中采购领域知识产权侵权纠纷提供专业 判定支持，并建立行政裁决快速通道，简化审理程序、压缩结案时间，同时，鼓励、组织专利侵权纠纷 当事人通过自行和解或行政调解等方式，提升纠纷化解效率。两部门将加强对专利侵权行为的联合处 置，及时采取撤网、取消中选资格等措施制止专利侵权行为，通过部门协同实现"信息共享—专业判定 —快速处 ...